Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Vaccine Immunol ; 14(8): 978-83, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17596426

ABSTRACT

The threat of a new influenza pandemic has led to renewed interest in dose-sparing vaccination strategies such as intradermal immunization and the use of adjuvanted vaccines. In this study we compared the quality and kinetics of the serum antibody response elicited in mice after one or two immunizations with a split influenza A (H3N2) virus, using three different low-dose vaccination strategies. The mice were divided into four groups, receiving either a low-dose vaccine (3 microg hemagglutinin [HA]) intradermally or intramuscularly with or without aluminum adjuvant or the normal human vaccine dose (15 microg HA) intramuscularly. Sera were collected weekly after vaccination and tested in the hemagglutination inhibition, virus neutralization, and enzyme-linked immunosorbent assays. The antibody responses induced after intradermal or intramuscular low-dose vaccinations were similar and lower than those observed after the human vaccine dose. However, low-dose adjuvanted vaccine elicited a serum antibody response comparable to that elicited by the human dose, although the second immunization did not result in any increase in cross-reactive hemagglutination inhibition antibodies, and the peak serum antibody response was observed 1 week later than in the other vaccination groups. Our murine data suggest that the low-dose intradermal route does not show any obvious advantage over the low-dose intramuscular route in inducing a serum antibody response and that none of the low-dose vaccination strategies is as effective as intramuscular vaccination with the normal human dose. However, the low-dose aluminum-adjuvanted vaccine could present a feasible alternative in case of limited vaccine supply.


Subject(s)
Antibodies, Viral/blood , Influenza A Virus, H3N2 Subtype/immunology , Influenza Vaccines/administration & dosage , Influenza, Human/immunology , Animals , Dose-Response Relationship, Immunologic , Enzyme-Linked Immunosorbent Assay , Female , Hemagglutination Inhibition Tests , Hemagglutinin Glycoproteins, Influenza Virus/immunology , Humans , Influenza Vaccines/immunology , Influenza, Human/prevention & control , Influenza, Human/virology , Kinetics , Mice , Models, Animal , Neutralization Tests , Vaccination
2.
Int J Chron Obstruct Pulmon Dis ; 2(3): 229-40, 2007.
Article in English | MEDLINE | ID: mdl-18229561

ABSTRACT

Influenza is a major respiratory pathogen, which exerts a huge human and economic toll on society. Influenza is a vaccine preventable disease, however, the vaccine strains must be annually updated due to the continuous antigenic changes in the virus. Inactivated influenza vaccines have been used for over 50 years and have an excellent safety record. Annual vaccination is therefore recommended for all individuals with serious medical conditions, like COPD, and protects the vaccinee against influenza illness and also against hospitalization and death. In COPD patients, influenza infection can lead to exacerbations resulting in reduced quality of life, hospitalization and death in the most severe cases. Although there is only limited literature on the use of influenza vaccination solely in COPD patients, there is clearly enough evidence to recommend annual vaccination in this group. This review will focus on influenza virus and prophylaxis with inactivated influenza vaccines in COPD patients and other "at risk" groups to reduce morbidity, save lives, and reduce health care costs.


Subject(s)
Influenza Vaccines/therapeutic use , Influenza, Human/drug therapy , Influenza, Human/prevention & control , Pulmonary Disease, Chronic Obstructive , Vaccines, Inactivated , Contraindications , Health Expenditures , Humans , Influenza A virus/drug effects , Influenza A virus/pathogenicity , Influenza B virus/drug effects , Influenza B virus/pathogenicity , Influenza, Human/epidemiology , Influenza, Human/virology , Norway/epidemiology , Pulmonary Disease, Chronic Obstructive/physiopathology , Vaccines, Inactivated/therapeutic use
3.
Vaccine ; 24(44-46): 6577-80, 2006 Nov 10.
Article in English | MEDLINE | ID: mdl-16842889

ABSTRACT

Studies of the immune response after influenza vaccination in man, with focus on the immune activity occurring locally at mucosal surfaces and in associated lymphoid tissue, provide a valuable insight into immunity to influenza. The aim of influenza vaccination is to develop immunological memory resulting in enhanced rapid specific response upon subsequent influenza encounter. The tonsils are thought to play an important role as an activating, effector and memory site for immune responses against influenza. We have shown that normally high numbers of influenza-specific antibody secreting cells (ASC) are present in the nasal mucosa of healthy adults but upon parenteral vaccination the numbers remain stable. However, a rapid transient increase in influenza-specific ASC is observed in the tonsils and peripheral blood after vaccination. In the tonsils and blood, parenteral vaccination results in a significant decrease in CD4(+) cells upon vaccination, which are probably recruited to the draining lymph node.


Subject(s)
Antibody Formation/drug effects , Immunity, Cellular/drug effects , Influenza Vaccines/administration & dosage , Influenza, Human/prevention & control , Lymphocytes/physiology , Palatine Tonsil/drug effects , Antibody Formation/immunology , Humans , Influenza Vaccines/immunology , Influenza, Human/immunology , Influenza, Human/virology , Infusions, Parenteral , Lymphocytes/immunology , Palatine Tonsil/immunology , Vaccination
4.
Vaccine ; 24(44-46): 6585-7, 2006 Nov 10.
Article in English | MEDLINE | ID: mdl-16839650

ABSTRACT

Recently the urgency of developing a pandemic influenza vaccine has lead to the re-evaluation of the use of whole virus vaccine. We have compared the humoral immune response and the protective efficacy of whole and split influenza virus vaccines in mice. Whole virus vaccine was more immunogenic particularly after the first dose of vaccine, generally eliciting higher numbers of systemic antibody secreting cells and an earlier and higher neutralising antibody response. Immunisation with one dose of whole virus vaccine more effectively reduced viral shedding upon non-lethal homologous viral challenge, but two doses of split virus vaccine was most effective at limiting viral replication and this was correlated with high influenza specific serum IgG concentrations. The two vaccine formulations induced different T helper profiles particularly after one dose of vaccine; split virus vaccine induced a type 2 bias response, whereas whole virus vaccine elicited a dominant type 1 response.


Subject(s)
Antibodies, Viral/blood , Antibody Formation/drug effects , Antibody-Producing Cells/drug effects , Influenza Vaccines/administration & dosage , Influenza Vaccines/immunology , Orthomyxoviridae Infections/prevention & control , Orthomyxoviridae/drug effects , Animals , Antibody-Producing Cells/immunology , Disease Models, Animal , Immunoglobulin G/biosynthesis , Immunoglobulin G/blood , Mice , Mice, Inbred BALB C , Orthomyxoviridae/growth & development , Orthomyxoviridae/immunology , Orthomyxoviridae Infections/immunology , Vaccines, Inactivated/administration & dosage , Vaccines, Inactivated/immunology
SELECTION OF CITATIONS
SEARCH DETAIL